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Mavoglurant in Fragile X 
Syndrome: Results of two open-
label, extension trials in adults and 
adolescents
Randi Hagerman1, Sebastien Jacquemont2,3, Elizabeth Berry-Kravis4, Vincent Des 
Portes5, Andrew Stanfield6, Barbara Koumaras7, Gerd Rosenkranz8, Alessandra Murgia9, 
Christian Wolf  10, George Apostol8 & Florian von Raison8
Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and 
developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 
antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to 
demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, 
phase IIb studies in adults and adolescents with FXS. Here we report the long-term safety (primary 
endpoint) and efficacy (secondary endpoint) results of the open-label extensions. Adolescent (n = 119, 
aged 12–19 years) and adult (n = 148, aged 18–45 years) participants received up to 100 mg bid 
mavoglurant for up to 34 months. Both extension studies were terminated prematurely due to lack 
of proven efficacy in the core studies. Mavoglurant was well tolerated with no new safety signal. Five 
percent of adults and 16.9 percent of adolescents discontinued treatment due to adverse events. 
Gradual and consistent behavioral improvements as measured by the ABC-CFX scale were observed, 
which were numerically superior to those seen in the placebo arm of the core studies. These two 
extension studies confirm the long-term safety of mavoglurant in FXS, but further investigations are 
required to determine whether and under which conditions the significant preclinical results obtained 
with mGluR5 inhibition can translate to humans.
Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental 
disabilities and has an estimated prevalence of approximately 1 in 4,000 males and 1 in 8,000 females1,2. FXS is 
typically caused by an unstable trinucleotide (CGG) repeat expansion within the promoter region of the frag-
ile X mental retardation 1 gene (FMR1), leading to partial or complete loss of the fragile X mental retardation 
protein (FMRP)3,4. The FXS phenotype varies but often includes symptoms of anxiety, perseverative behavior, 
attention-deficit/hyperactivity disorder (ADHD), seizures, self-injurious behavior, hyperarousal, hypersensitivity, 
aggression, impaired sleep, and impaired cognition5–7. These symptoms are associated with a considerable burden 
on patients and their caregivers from both a health-related quality of life and economic perspective8–10.
There are currently no approved curative therapies for FXS and management approaches focus on symp-
tomatic treatment of comorbid behavioral problems and psychiatric diagnoses (e.g., stimulants for ADHD or 
selective serotonin reuptake inhibitors [SSRIs] for anxiety disorders associated with FXS). Recent advances in our 
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understanding of the neurobiological basis of FXS have led to the early development and clinical trials of several 
new potential targeted therapies for FXS11.
FMRP regulates mRNA translation and protein production at the synapse via multiple synaptic receptors that 
include the Group I metabotropic glutamate receptors (mGluR). Loss of FMRP leads to abnormalities of synaptic 
transmission and dendritic spine architecture that are thought to underlie the behavioral and cognitive symptoms 
of FXS12. Mavoglurant (AFQ056) is a selective mGluR5 antagonist that inhibits activation of the mGluR5 recep-
tor thus reducing the synaptic defects occurring due to absence of FMRP13. Preclinical studies have shown that 
mavoglurant rescues the dendritic spine architecture and restores social behavior in an FXS mouse model (FMR1 
knockout mice)14,15. A small-scale phase IIa, placebo-controlled clinical trial of 30 adult male patients with FXS 
suggested efficacy of mavoglurant in the subpopulation of patients with a fully methylated FMR1 gene16, which 
supported a larger-scale development program.
Mavoglurant was evaluated as treatment for the behavioral symptoms of FXS in two 12-week, multina-
tional, randomized, double-blind, placebo-controlled Phase IIb clinical studies in adolescent and adult patients 
(NCT01357239 and NCT01253629, respectively). These studies failed to meet their primary objective of showing 
mavoglurant efficacy versus placebo in reducing the Aberrant Behavior Checklist – Community edition Fragile 
X Syndrome specific algorithm (ABC-CFX) total score over 12 weeks of treatment in the fully methylated group 
of patients, or secondarily in the partially methylated or combined groups17. Key secondary efficacy objectives, 
including Clinical Global Impression – Improvement (CGI-I) assessment, were also not significantly different for 
mavoglurant versus placebo17,18. However, mavoglurant was found to be generally safe and well tolerated over this 
12-week period.
There are a number of potential reasons why mavoglurant was not found to be effective in these studies. 
Among these is the relatively brief intervention period in the context of a lifelong severe neurodevelopmental 
disorder. Two open-label, extension studies in adolescent and adult patients with FXS were initiated as part of 
the ongoing Phase IIb program to ensure that the trial participants had continued access to the study drug. These 
extension studies allowed us to further evaluate the safety and efficacy profile of mavoglurant over a longer treat-
ment period.
Methods
Study design. These studies were multinational, multicenter, single-arm, flexible-dose, open-label, phase IIb 
extension of core studies conducted in adolescent (NCT01433354; September 13, 2011) and adult (NCT01348087; 
May 5, 2011) patients with FXS. The total duration of each extension study was planned to be 24 months or until 
the study drug would have become available on the market (whichever would have occurred later). The protocol 
also provided for extension of treatment beyond 24 months, if required. The primary objective of both studies was 
to evaluate the long-term safety of mavoglurant in these two populations, while secondary objectives included 
evaluation of its long-term efficacy.
The study protocols were approved by the Independent Ethics Committee or Institutional Review Board 
(detailed in Tables S1 and S2) at each center. The studies were conducted according to the ethical principles of the 
Declaration of Helsinki. For both the adolescent and adult studies, the caregiver, legal guardian or legally accept-
able representative had to be able to communicate well with the investigator and to understand and support the 
study requirements by providing written informed consent. If a patient was capable of doing so, he/she should 
have provided his/her written assent (in accordance with local ethical/regulatory requirements).
Participants. Eligible participants were males or females who had previously participated in a clinical study 
of mavoglurant in an FXS population. They should be 12–17 years (adolescent study) and at least 18 years of age 
(adult study) at the time of screening into the previous study, or at least 12 years of age at the time of entry in 
the current adolescent study. Participants were required to have a caregiver(s) who spent at least six hours per 
day with them to supervise treatment and assess outcomes. Major exclusion criteria included a history and/or 
presence of: any advanced, severe or unstable disease; schizophrenia; bipolar disorder; psychosis; confusional 
states and/or repeated hallucinations; clinically significant ECG abnormalities; seizure disorder uncontrolled or 
resistant to therapy within the past 2 years; suicidal behavior or considered to have a high suicidal risk; and severe 
self-injurious behavior. Patients who used potent inhibitors or inducers of CYP3A4 ≤6 weeks before the exten-
sion study baseline were also excluded.
Treatment. All patients initiated mavoglurant treatment at a starting dose of 25 mg bid and were up-titrated 
at weekly intervals to 50 mg bid, 75 mg bid, and 100 mg bid (Fig. S1). Dose adjustments were permitted to manage 
tolerability and to ensure that patients reached their highest tolerated mavoglurant dose, not to exceed 100 mg 
bid. Patients unable to tolerate the 25-mg bid dose were discontinued. Concomitant medication to treat comorbid 
behavioral symptoms was permitted but was to be maintained at stable doses during the study as much as possi-
ble. Glutamatergic drugs, lithium, warfarin, digoxin, moderate or strong inducers or inhibitors of CYP3A4, and 
any other investigational drugs were not permitted.
The dosing regimen was to be overseen and documented by the caregiver, where appropriate, to ensure that it 
was correctly followed.
Outcomes. Safety. Safety assessments involved collection of reports on all adverse events (AEs) and serious 
adverse events (SAEs), standard clinical laboratory evaluations, and electrocardiograms (ECGs), as well as regular 
physical examination and assessment of vital signs, body height and weight, and pregnancy status.
Behavioral measures and clinical impression. ABC-CFX: ABC-C assesses problem behaviors of children and 
adults with developmental disabilities at home using a 58-item questionnaire completed by the caregiver scoring 
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each item from 0 (“not at all a problem”) to 3 (“problem is severe in degree”)19,20. The modified ABC-CFX repre-
sents a re-factored 55-item version of the scale based on ratings from a large FXS population and consists of six 
subscales (irritability, lethargy/withdrawal, stereotypic behavior, hyperactivity, inappropriate speech, and social 
avoidance), and the total score is graded from 0 to 16521.
Clinical Global Impression (CGI) assessment: Baseline severity of illness was assessed using the 7-point CGI-S 
scale (from “normal” to “among the most extremely ill patients”). Additionally, global changes in symptoms 
(CGI-I) were rated on a 7-point scale (from “very much improved” to “very much worse”) relative to baseline at 
entry into the extension study based on clinical evaluation and caregiver reports22.
Repetitive Behavior Scale – Revised (RBS-R): RBS-R is a caregiver-rated questionnaire assessing repetitive 
behaviors across six domains (ritualistic behavior, sameness behavior, stereotypic behavior, self-injurious behav-
ior, compulsive behavior, and restricted interests)23. Each domain is scored from 0 (behavior does not occur) to 3 
(behavior occurs and it is a severe problem) with a resulting total score between 0 and 129.
Social Responsiveness Scale (SRS): This scale identifies the presence and assesses the extent of autistic spec-
trum symptoms24. It is a 65-item questionnaire, rating behaviors from 0 (not true) to 3 (almost always true) com-
pleted by the caregiver, with a total score ranging from 0 to 195.
For all of these scales, a negative change from baseline indicates improvement.
Statistical analysis. Variables were summarized using descriptive statistics. The number of participants 
enrolled was determined by the number of eligible patients and not based on power calculations. Patient disposi-
tion and efficacy outcomes were analyzed using the “full analysis set,” which included all patients who received at 
least one dose of study medication during the extension study.
Safety was analyzed using the “safety set,” which consisted of all patients who received at least one dose of 
study medication during the extension study and had at least one safety assessment occurring after the first dose 
of extension study medication.
Role of funding source. The funder of the study was involved in the design and conduct of the study; col-
lection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; 
and decision to submit the manuscript for publication. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to submit for publication. All authors have approved the 
final version of the paper.
Results
Baseline characteristics and drug exposure. The adolescent extension study was conducted between 
November 23, 2011 and September 17, 2014, whereas the adult extension study was conducted between August 
19, 2011 and September 10, 2014.
In total, 119 out of 139 (86%) adolescents and 148 out of 175 (85%) adults entered in the extension studies 
from their respective double-blind, core studies (Fig. 1)17. Baseline demographics and characteristics for both 
studies are summarized in Table 1.
Both extension studies were terminated prematurely based on a failure to show efficacy for mavoglurant ver-
sus placebo in the core studies, and all patients discontinued. The majority of discontinuation was due to early 
termination of the studies (Fig. 1).
Mean ± standard deviation (SD) exposure time to mavoglurant in the adolescent study was 513.2 ± 274.94 
days, equivalent to 167.2 patient-years. Mean ± SD exposure time in the adult study was 538.3 ± 316.23 days, 
equivalent to 218.1 patient-years. Overall, 91 patients (76.5%) in the adolescent study and 135 (91.2%) in the adult 
study received the intended mavoglurant 100 mg bid dose for ≥1 day. In both studies, the overall proportion of 
patients receiving mavoglurant 100 mg bid remained >69% from Day 22–28 onward. All treated patients were 
included in the “full analysis sets” and “safety sets” for analysis.
Figure 1. Patient flow*. *The discontinuations noted in this graph are those discontinuations that occurred 
before study termination. All patients eventually discontinued when the studies ended prematurely.
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Safety and tolerability. The majority of patients in the adolescent study (92.4%) and adult study (93.2%) 
reported at least one AE (Tables 2 and 3). The most frequently occurring AEs regardless of dose at onset 
were nasopharyngitis (adolescent study: 29.4%/adult study: 18.2%), insomnia (21.0%/15.5%), aggression 
(16.0%/15.5%) and upper respiratory tract infection (14.3%/16.2%). The rate of AEs was the highest in patients 
receiving the 100-mg bid dose of mavoglurant, reflecting, at least in part, the greater duration of time that patients 
spent at this highest dose.
AEs were predominantly mild or moderate in severity for both the adolescent study (86%) and adult study 
(77%). Four patients in the adolescent study (3.4%) and seven in the adult study (4.7%) experienced an SAE. SAEs 
in the adolescent study were one case each of aggression, hip joint dislocation with subsequent respiratory tract 
infection as a complication of surgery, foreign body ingestion, and appendicitis. The incident of severe aggression 
was considered by the investigators as possibly related to study medication, whereas the other three SAEs were 
considered unrelated.
SAEs in the adult study were: five patients with one or more psychiatric disorder symptoms (aggression, anx-
iety, agitation, panic attack, and visual and auditory hallucinations) and one patient each with epilepsy/seizure 
and liver enzyme elevations. SAEs of aggression and visual hallucinations in one patient, aggression in a second 
patient, and liver enzyme elevations in a third patient were considered possibly related to study drug. All other 
SAEs were considered unrelated.
Six patients in the adolescent study (5.0%) and 25 in the adult study (16.9%) discontinued study treatment 
due to an AE. The most frequently reported class of AEs leading to discontinuation were psychiatric disorders 
(adolescent study: 4.2%/adult study: 12.2%) and nervous system disorders including dizziness, speech disorder, 
headache, incoherent/poor quality sleep, and psychomotor hyperactivity (adolescent study: 2.5%/adult study: 
4.1%). No deaths were reported in either study.
Clinical effect. ABC-CFX. Two categories of patients were analyzed separately, those who received a rela-
tively continuous mavoglurant treatment from the core study, and those who did not (i.e. coming from the pla-
cebo arm or with a larger treatment gap; see Fig. 2 for more details).
In both studies and both patient categories, a gradual improvement in the behavioral symptoms of FXS, as 
measured by a reduction in mean ABC-CFX total scores, was observed from the core study baseline (Fig. 2a,b). 
The mean (±SD) overall change in ABC-CFX total score from the extension baseline to Week 52 was −13.4 
(±22.1) and −13.3 (±19.2) in the adolescent and adult studies, respectively.
CGI-I. The distribution of patient CGI-I ratings over time are summarized in Fig. 2c and d and detailed in 
Table S3. At 12 weeks, clinicians rated the majority of patients (>75%) in both studies as showing an improvement 
Demographic variable
Adolescent study
(N = 119)
Adult study
(N = 148)
Age (years) 15.2 (1.8) 26.6 (6.9)
  Range 12–19 18–45
Sex, male, n (%) 106 (89.1) 138 (93.2)
Race, n (%)
  Caucasian 110 (92.4) 142 (95.9)
  Black 2 (1.7) 2 (1.4)
  Asian 3 (2.5) 0
  Native American 1 (0.8) 0
  Other 3 (2.5) 4 (2.7)
Weight (kg) 64.5 (16.9) 80.9 (17.9)
  Range 34.8–122.5 41.4–131.0
ABC-CFX total score 49.8 (29.0) 43.4 (26.8)
  Range 6 to 146 2 to 134
CGI-S score, n (%)
  2 (Borderline mentally ill) 0 0
  3 (Mildly ill) 5 (4.2) 3 (2.0)
  4 (Moderately ill) 54 (45.4) 64 (43.2)
  5 (Markedly ill) 43 (36.1) 55 (37.2)
  6 (Severely ill) 17 (14.3) 22 (14.9)
  7 (Among the most 
extremely ill) 0 4 (2.7)
IQ score 41.0 (9.3) 47.0 (7.0)
  Range 30–76 36–69
Table 1. Demographics and extension study baseline characteristics (full analysis set). Data are mean (standard 
deviation [SD]) unless indicated otherwise. ABC-CFX, Aberrant Behavior Checklist – Community edition using 
the FXS specific algorithm; BMI, body mass index; CGI-S, Clinical Global Impression – Severity scale; IQ, 
Intelligence Quotient.
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in their global FXS symptoms from the extension study baseline. A continued improvement in CGI-I score distri-
bution was observed over the duration of the extension study. Few patients (n =≤ 6 at any time point) achieved a 
CGI-I rating of “very much improved” or of “minimally worse,” “much worse” or “very much worse.”
RBS-R and SRS. Patients’ repetitive behavior and social interactions, as measured by the RBS-R and SRS scales, 
respectively, also showed a gradual improvement from the extension study baseline (Fig. 3 and Table S4).
Discussion
The primary objective of these open-label, single-arm, extension studies was to evaluate the long-term safety 
of mavoglurant in adolescents or adults with FXS. Although the studies were terminated prematurely, the 
extent of study drug exposure provides considerable insight into the long-term safety and tolerability profile of 
mavoglurant.
The results showed that in adolescent (age 12–19 years) and adult (age 18–45 years) patients with FXS, 
long-term treatment with mavoglurant was generally well tolerated with low rates of SAEs and no new safety 
findings beyond those observed in the 12-week double-blind core studies of adolescents or adults. Given the 
long duration of the treatment period, the majority of patients experienced at least one AE but these events were 
predominantly mild or moderate in severity and the majority were considered by the investigator to be unrelated 
to the drug. More patients showed aggressive behavior on the 100 mg dose (11.1% and 8.9% in the adolescent and 
Preferred term
Total n 
(%)
Mavoglurant 
25 mg bid n (%)
Mavoglurant 
50 mg bid n (%)
Mavoglurant 
75 mg bid n (%)
Mavoglurant 
100 mg bid n (%)
Adolescent study N = 119 N = 119 N = 118 N = 116 N = 108
Patients with any adverse event 110 (92.4) 36 (30.3) 41 (34.7) 44 (37.9) 90 (83.3)
  Nasopharyngitis 35 (29.4) 7 (5.9) 3 (2.5) 8 (6.9) 25 (23.1)
  Insomnia 25 (21.0) 4 (3.4) 10 (8.5) 5 (4.3) 12 (11.1)
  Aggression 19 (16.0) 3 (2.5) 3 (2.5) 4 (3.4) 12 (11.1)
  Initial insomnia 18 (15.1) 3 (2.5) 2 (1.7) 4 (3.4) 9 (8.3)
  Upper respiratory tract infection 17 (14.3) 3 (2.5) 5 (4.2) 3 (2.6) 9 (8.3)
  Anxiety 15 (12.6) 3 (2.5) 1 (0.8) 0 11 (10.2)
  Headache 15 (12.6) 4 (3.4) 1 (0.8) 4 (3.4) 8 (7.4)
  Irritability 15 (12.6) 3 (2.5) 1 (0.8) 3 (2.6) 9 (8.3)
  Vomiting 13 (10.9) 2 (1.7) 5 (4.2) 0 8 (7.4)
  Cough 12 (10.1) 1 (0.8) 1 (0.8) 4 (3.4) 7 (6.5)
  Diarrhea 12 (10.1) 2 (1.7) 4 (3.4) 0 5 (4.6)
Patients with any serious adverse event 4 (3.4) 0 1 (0.8) 0 3 (2.8)
Patients with any adverse event leading to 
study drug discontinuation 6 (5.0) 2 (1.7) 2 (1.7) 0 3 (2.8)
Table 2. Most frequent adverse events* in adolescent patients during the extension period, by last dose before 
event onset (safety population). *Incidence ≥10% in any group.
Preferred term
Total n 
(%)
Mavoglurant 
25 mg bid n (%)
Mavoglurant 
50 mg bid n (%)
Mavoglurant 
75 mg bid n (%)
Mavoglurant 
100 mg bid n (%)
Adult study N = 148 N = 147 N = 148 N = 141 N = 135
Patients with any adverse event 138 (93.2) 49 (33.3) 47 (31.8) 50 (35.5) 112 (83.0)
  Nasopharyngitis 27 (18.2) 2 (1.4) 4 (2.7) 3 (2.1) 21 (15.6)
  Upper respiratory tract infection 24 (16.2) 4 (2.7) 1 (0.7) 3 (2.1) 16 (11.9)
  Aggression 23 (15.5) 6 (4.1) 8 (5.4) 6 (4.3) 12 (8.9)
  Insomnia 23 (15.5) 4 (2.7) 3 (2.0) 7 (5.0) 12 (8.9)
  Headache 21 (14.2) 4 (2.7) 3 (2.0) 7 (5.0) 14 (10.4)
  Vomiting 18 (12.2) 1 (0.7) 2 (1.4) 2 (1.4) 14 (10.4)
  Anxiety 16 (10.8) 1 (0.7) 3 (2.0) 3 (2.1) 10 (7.4)
  Cough 16 (10.8) 4 (2.7) 0 2 (1.4) 9 (6.7)
  Agitation 15 (10.1) 0 1 (0.7) 3 (2.1) 12 (8.9)
  Irritability 15 (10.1) 0 7 (4.7) 4 (2.8) 6 (4.4)
Patients with any serious adverse event 7 (4.7) 1 (0.7) 0 1 (0.7) 6 (4.4)
Patients with any adverse event leading to 
study drug discontinuation 25 (16.9) 5 (3.4) 5 (3.4) 5 (3.5) 12 (8.9)
Table 3. Most frequent adverse events* in adult patients during the extension period, by last dose on, or before, 
event onset (safety population). *Incidence ≥10% in any group.
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adult studies, respectively). This could be the result of the longer exposure to this dose rather than a dose effect; 
in any case future treatment should be carefully monitored and the dose should be lowered if activation and/
or aggression occur. Overall, 11 patients experienced an SAE, including four patients for whom the SAEs were 
possibly related to mavoglurant treatment.
Figure 2. ABC-CFX LS Mean Change from core study baseline in (a) adolescents and (b) adults and distribution 
of CGI-I ratings from extension study baseline in (c) adolescents and (d) adults*. Category 1: treated with 
mavoglurant in core study and entered the open-label extension study within 1 week of core study completion. 
Category 2: treated with placebo in core study or entered the open-label extension study more than 1 week after 
core study completion. Ext, extension; SE, standard error; WK, Week. *All patients regardless of methylation status.
www.nature.com/scientificreports/
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No notable differences in the safety profile of mavoglurant were observed between adolescent and adult 
patients. Mean exposure to mavoglurant was lower in the adolescent versus the adult study (167.2 patient-years 
vs. 218.1 patient-years), and a lower proportion of patients in the adolescent study received the intended mavo-
glurant 100-mg bid dose for ≥1 day (76.5% vs. 91.2%). These differences are likely to be due to the smaller size 
and body weight of adolescent patients and consequent relative greater exposure at an equivalent dose level. 
Moreover, the lower number of patients enrolled in the adolescent study, as well as the later start date with an 
overall shorter study duration relative to the adult study (~34 vs 37 months) could affect patient-years.
Both studies showed a gradual and consistent improvement in FXS behavioral symptom control as measured 
by ABC-CFX and CGI-I scores. These improvements over the extension baseline were apparent on all behavioral 
measures without loss of effect in a subgroup over time. The level of improvement in terms of mean (±SD) change 
in ABC-CFX total scores from extension baseline after 52 weeks of mavoglurant treatment in the extensions stud-
ies (−13.4 [±22.1] and −13.3 [±19.2] in adolescents and adults, respectively) was numerically higher than that 
observed with placebo at 12 weeks in the core studies (−6.2 [ ±17.86] and −10.9 [±15.61], respectively) (data 
on file)17. Trends toward improvement in RBS-R and SRS scores were also observed in the open-label extension 
studies.
These positive trends should be interpreted with caution given that the studies do not have a control group 
and thus cannot make comparative assessment of efficacy. It would be expected that placebo effects would taper 
off after such a long period, however there is some data to indicate that placebo responses are stable over time 
(up to three years) in populations with developmental disorders25. Other possible limitations of the study designs 
include bias associated with open-label treatment and selection/survivor bias due to enrollment of patients who 
successfully completed prior core studies of mavoglurant. In addition, a relatively large proportion of patients dis-
continued study treatment before study termination (24.4% in the adolescent study and 46.6% in the adult study), 
including 17 (14.3%) and 35 (23.6%) patients, respectively, due to a perceived lack of efficacy. Thus, an ongoing 
improvement on three behavioral measures over the course of the study may also result from the selection of 
those patients perceived to be doing better independent of a drug effect rather than reflecting a subgroup of 
long-term responders. For all these reasons it was not deemed appropriate to test whether the observed improve-
ment over the core study was statistically significant.
Figure 3. RBS-R score from extension study baseline in (a) adolescents and (b) adults* and SRS score from 
extension study baseline in (c) adolescents and (d) adults*. RBS-R, Repetitive Behavior Scale – Revised; SE, 
standard error; SRS, Social Responsiveness Scale. *All patients regardless of methylation status.
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In any case, the above interpretation of the results does not preclude the possibility of mavoglurant being 
effective in a different experimental setting (younger age group, longer trial periods to assess cognition and devel-
opment, applying interventional measures such as speech/reading training, or adding a drug with a synergistic 
mechanism of action). It should also be noted that, while many families observed an improvement in language, 
focus and aptitude to get things done, job performance and problem-solving abilities, possible effects on cogni-
tion were not assessed. Although work in this area is ongoing, there is no consensus yet on which specific meas-
ures should be used to evaluate population with moderate or severe intellectual disabilities, who often perform 
at or below the floor of standardized cognitive test26. Future studies of mavoglurant should evaluate cognitive 
benefits and initiate treatment at a younger age when antagonism of the mGluR pathway is more likely to facilitate 
normalization of brain development in children with FXS.
The FXS clinical trial field has undergone significant growth in recent years, and its future, including the future 
of the fmr1 KO mouse model and more generally the translation of preclinical research, have been discussed 
in recent reviews26–29. Assessment measures including electroencephalogram (EEG) recordings and functional 
magnetic resonance imaging (fMRI), which can be applied in preclinical models as well as clinically, could help 
bridge the translation treatment gap26,27. Altogether, such studies would shed some light on the current discon-
nect between the restorative preclinical effects of mGluR5 blockers repeatedly and extensively observed in animal 
models, and the lack of significant clinical effect observed in humans.
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